Anti-programmed Death-1 Antibody, Immune Checkpoint Inhibitors, Metastatic Cervical Carcinoma, Objective Remission Rate, Overall Survival, Persistent Advanced Cervical Carcinoma, Progression-free Survival, Radiotherapy, Recurrent Cervical Carcinoma, Severe Adverse Events
Conditions
Brief summary
This study is to investigate retrospectively the effects of combination of immune checkpoint inhibitors anti-programmed death-1 antibody (PD-1 antibody) and radiotherapy for recurrent, metastatic and persistent advanced cervical carcinomas. Patients may or may not accept PD-1 antibody as maintenance therapy. Patients are followed up and the survival outcomes are evaluated. The primary endpoint are objective remission rate. The secondary endpoints are progression-free survival, overall survival and severe adverse events.
Interventions
COMBINATION_PRODUCTRadiotherapy for targeted lesions and PD-1 antibody
Radiotherapy for targeted lesions in all enrolled participants, with concurrent PD-1 antibody. Patients may or may not accept subsequent PD-1 as maintenance therapy.
Sponsors
Lei Li
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged 18 years or older * Confirmed of recurrent, metastatic, and persistent advanced cervical cancer * Confirmed of subtypes of cervical squamous carcinoma, adenocarcinoma and adenosquamous carcinoma * Accepting radiotherapy with concurrent anti PD-1 therapy * With detailed follow-up outcomes
Exclusion criteria
\- Not meeting all of the inclusion criteria
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective remission rate | One year | Objective remission rate in one month after the end of radiotherapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival | One year | Progression-free survival after the end of radiotherapy |
| Overall survival | One year | Overall survival after the end of radiotherapy |
| Severe adverse events | Two years | Severe adverse events during the radiotherapy and the follow-up stage |
Countries
China
Contacts
Primary ContactLei Li, M.D.
Outcome results
None listed